Therapeutic and diagnostic methods for cancer

Craig Anthony Cummings , Yan Li , Sarah Margaret Shagan , Erica Beth Schleifman

2023
Therapeutic and diagnostic methods for cancer

Craig Anthony Cummings , Yan Li , Sarah Margaret Paul , Erica Beth Schleifman

2019
INDUCIBLE NUCLEIC ACID TARGETS FOR DETECTION OF PATHOGENS, METHODS AND COMPOSITIONS THEREOF

Priya BALACHANDRAN , Craig CUMMINGS , Olga PETRAUSKENE , Hemant PAWAR

2
2012
Enterohemorrhagic e. coli o104:h4 assays

Pius Brzoska , Alain Rico , Craig Cummings , Yongmei ("Alexis") Ji

3
2012
Methods for detection of multiple target nucleic acids

Maxim Brevnov , Wayne Ge , Daniel Kephart , Darcy Myers

1
2014
COMPOSITIONS AND METHODS FOR DETECTION OF SALMONELLA SPECIES

Olga Petrauskene , Lily Wong , Reyes Allison De Los , Craig Cummings

3
2015
4
2012
Compositions and methods for detection of cronobacter spp. and cronobacter species and strains

Pius Brzoska , Lovorka Degoricija , Manohar Furtado , Harrison Leong

5
2012
Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.

Fatema A. Legrand , David R. Gandara , Sanjeev Mariathasan , Thomas Powles
Journal of Clinical Oncology 36 12000 -12000

26
2018
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.

Philippe Armand , Yasuhiro Oki , Donna S. Neuberg , Malek Faham
British Journal of Haematology 163 ( 1) 123 -126

81
2013
Effect of anti-CTLA-4 antibody treatment on T-cell repertoire evolution in treated cancer patients.

Edward Cha , Yafei Hou , Mark Klinger , Craig Cummings
Journal of Clinical Oncology 31 3020 -3020

3
2013
Association of maintenance of pre-existing memory T-cell responses following anti-CTLA-4 antibody treatment with improved overall survival.

Lawrence Fong , Edward Cha , Mark Klinger , Yafei Hou
Journal of Clinical Oncology 32 3016 -3016

2
2014
OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients

Marcin Kowanetz , Wei Zou , David Shames , Craig Cummings
Journal of Thoracic Oncology 12 ( 1) S321 -S322

43
2017
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.

Xiaoji Chen , Ching-Wei Chang , Jill M. Spoerke , Kathryn E. Yoh
Clinical Cancer Research 25 ( 7) 2254 -2263

63
2019
Molecular determinants of response to PD-L1 blockade across tumor types

Romain Banchereau , Ning Leng , Oliver Zill , Ethan Sokol
Nature communications 12 ( 1) 3969

49
2021
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

Zoe June F Assaf , Wei Zou , Alexander D Fine , Mark A Socinski
Nature Medicine 29 ( 4) 859 -868

36
2023
A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab

David Fabrizio , Daniel Lieber , Christine Malboeuf , Jacob Silterra
Cancer Research 78 ( 13_Supplement) 5706 -5706

32
2018
T-cell repertoire turnover induced by anti-CTLA-4 antibody treatment in cancer patients

Lawrence H Fong , Edward Cha , Mark Klinger , Yafei Hou
Cancer Research 74 ( 19_Supplement) 5017 -5017

2014
Comparison of gene expression platforms: RNA-Seq, Fluidigm, and Nanostring

Erica B Schleifman , Maipelo Motlhabi , Craig Cummings , Rin Nakamura
Cancer Research 75 ( 15_Supplement) 4901 -4901

2015